Document is current
Any future updates will be listed below
-
Authors
Zhou, Zinan https://orcid.org/0000-0003-2014-3650
Kim, Junho
Huang, August Yue https://orcid.org/0000-0002-0416-2854
Nolan, Matthew
Park, Junseok
Doan, Ryan
Shin, Taehwan
Miller, Michael B. https://orcid.org/0000-0002-6205-3314
Bae, Mingyun
Zhao, Boxun https://orcid.org/0000-0003-2337-5756
Kim, Jinhyeong https://orcid.org/0009-0002-0466-3023
Chhouk, Brian
Morillo, Katherine
Yeh, Rebecca C.
Kenny, Connor
Neil, Jennifer E.
Lee, Chao-Zong
Ohkubo, Takuya https://orcid.org/0009-0005-0221-1594
Ravits, John
Ansorge, Olaf https://orcid.org/0000-0003-1825-5434
Ostrow, Lyle W. https://orcid.org/0000-0001-7158-5243
Lagier-Tourenne, Clotilde https://orcid.org/0000-0002-3058-8322
Lee, Eunjung Alice https://orcid.org/0000-0002-6574-9261
Walsh, Christopher A. https://orcid.org/0000-0002-0156-2238
- License Information
-
More Information
Article History
Received: 7 November 2023
Accepted: 11 March 2026
First Online: 15 April 2026
Competing interests
: C.L.-T. serves on the scientific advisory board and/or has received consulting fees from SOLA Biosciences, Libra Therapeutics, Arbor Biotechnologies, Dewpoint Therapeutics, Mitsubishi Tanabe Pharma Holdings America, Sanofi, AUTTX, Carthera, the Milken Institute and Applied Genetic Technologies. E.A.L. serves on the scientific advisory board of Genome Insight. C.A.W. is a paid consultant (cash, no equity) to CAMP4 Therapeutics (cash, no equity) and Maze Therapeutics (cash and equity), is a member of the scientific advisory board for Bioskryb Genomics (cash) and is a founding advisor for Mosaica Medicines (equity). These companies did not fund this research project and had no role in its conception or execution. The other authors declare no competing interests.
